AstraZeneca to set up $1.5-billion ADC production hub in Singapore
2024-05-20
抗体药物偶联物
Intending to bolster its growing precision oncology portfolio, AstraZeneca announced Monday plans to construct a new $1.5 billion production facility in Singapore for antibody-drug conjugates (ADCs).
Backed by the Singapore Economic Development Board, the new site will not only be AstraZeneca’s first manufacturing facility on the island nation, but also its first end-to-end ADC production unit. “Singapore is one of the world’s most attractive countries for investment given its reputation for excellence in complex manufacturing,” remarked AstraZeneca CEO Pascal Soriot.
The facility’s design and construction are slated to begin by the end of the year, with operational readiness expected by 2029. The company also noted that the site will incorporate sustainability and will have zero carbon emissions from day one of operations.
AstraZeneca’s ADC arsenal is led by Daiichi Sankyo-partnered Enhertu (trastuzumab deruxtecan), which recently scored an FDA nod as the first tumour-agnostic ADC. Meanwhile, datopotamab deruxtecan (dato-DXd) — a TROP2-directed ADCTROP2-directed ADC also co-developed with Daiichi — is under regulatory review in the US and EU. Additionally, the drugmaker’s pipeline holds a number of ADC assets in clinical and preclinical development, including one acquired from La Nova Medicines last year.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。